Looking back on what has transpired over the last several months, it is very interesting. I believe they know the success of the interim safety analysis and that is why they added DrPedder to the board. Is expertise in pushing through FDA approval is well documented. We all believe that the toxic financing was a stupid thing to do. Or was it? You cannot blame the note holders for shorting this down to peanuts. After all they will and have been well rewarded. The company needed this money to shore up the success of their future. This was the only way to do it since the share holders voted down the r/s. So, I believe they are sitting in a very unique positing to springboard their company to the next level. I’m not a pumper. I have many real shares in a real company with extreme potential.
Market Data 
Markets 
AI
